SCHEMBL2664599

SCHEMBL2664599

COC(=O)c1cnc(NC(=O)c2cc(OCc3ccccc3Cl)cc(OCc3ccccc3Cl)c2)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 5/20 0.56
RARA P10276 1/20 0.51
RARB P10826 1/20 0.51
RARG P13631 1/20 0.51
RAB9A P51151 3/20 0.46
NR4A2 P43354 2/20 0.46
NPC1 O15118 2/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
HDAC8 Q9BY41 2/20 0.43
KDM4E B2RXH2 2/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
CSNK2A2 P19784 1/20 0.42
CSNK2A1 P68400 1/20 0.42
RECQL P46063 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664601 0.90 GCK (0.64) GCKRARARARBRARGRAB9A
SCHEMBL2664598 0.86 GCK (0.61) GCKRARARARBRARGRAB9A
SCHEMBL12615087 0.86 GCK (0.49) GCKRARARARBRARGMAOB
SCHEMBL2664634 0.86 GCK (0.54) GCKRARARARBRARGRAB9A
SCHEMBL2664865 0.82 GCK (0.65) GCKRARARARBRARGRAB9A
SCHEMBL2664595 0.81 GCK (0.58) GCKRARARARBRARGRAB9A
SCHEMBL2664596 0.80 GCK (0.57) GCKRARARARBRARGRAB9A
SCHEMBL1796005 0.80 NR4A2 (0.60) GCKRAB9ANR4A2NPC1MAOA
SCHEMBL2664907 0.80 RAB9A (0.56) GCKRAB9ANR4A2NPC1MAOA
SCHEMBL1792201 0.79 GCK (0.64) GCKRARARARBRARGRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 GCK 2/4885RARA 3925/4885RARB 3902/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 GCK 2/4885RARA 3925/4885RARB 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.